3/2
09:27 am
help
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
Medium
Report
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
2/27
12:12 pm
help
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
Low
Report
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
2/26
12:23 pm
help
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
2/24
11:57 pm
help
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
Medium
Report
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
2/24
07:45 am
help
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Medium
Report
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
2/18
09:53 pm
help
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers [Yahoo! Finance]
Low
Report
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers [Yahoo! Finance]
2/17
07:30 am
help
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Medium
Report
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
2/13
07:31 am
help
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Low
Report
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
2/10
08:30 am
help
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Low
Report
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
2/10
07:56 am
help
Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]
Low
Report
Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]
2/10
07:30 am
help
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Low
Report
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
2/2
07:00 am
help
Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.
1/10
03:22 pm
help
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]
Low
Report
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]
1/5
08:04 am
help
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq [Yahoo! Finance]
High
Report
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq [Yahoo! Finance]
1/5
07:30 am
help
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
High
Report
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq